The overall health system in Russia, in particular the strategy, legal framework, and regulations as well as implementation of effective drugs policies together will have a major impact on the pharmaceutical market. What are the expectations for the Russian market and will these aspirations come to pass?
Moderators
Alexey Repik ,
President, Delovaya Rossiya (Business Russia)
Vladimir Shipkov ,
Executive Director, Association of International Pharmaceutical Manufacturers (AIPM)
Panellists
Alexey Repik ,
President, Delovaya Rossiya (Business Russia)
Alexey Repik ,
President, Delovaya Rossiya (Business Russia)
Alexey Repik ,
President, Delovaya Rossiya (Business Russia)
Mikhail Oseevskiy ,
President, Rostelecom
Larisa Popovich ,
Director, Institute for Health Economics, National Research University of the Higher School of Economics
Alexey Repik ,
President, Delovaya Rossiya (Business Russia)
Joseph Jimenez ,
Chief Executive Officer, Novartis AG
Sergey Tsyb ,
Deputy Minister of Industry and Trade of the Russian Federation
Vladimir Yablonsky ,
Director of the Branch Social Projects, Agency for Strategic Initiatives
Sergey Yastrebov ,
Governor of the Yaroslavl Region